Research Topics
| Robert W CarlsonSummaryAffiliation: Stanford University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Treatment of breast cancer in countries with limited resourcesRobert W Carlson
Department of Medicine, Stanford University, Stanford, California 94305, USA
Breast J 9:S67-74. 2003..Efforts to reduce the number of breast cancers diagnosed at an advanced stage thus have the potential to improve rates of survival while decreasing the use of limited resources...
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancerRobert W Carlson
Eastern Cooperative Oncology Group, Boston, MA, USA
Breast Cancer Res Treat 133:1049-56. 2012..Further studies of EGFR inhibition plus endocrine therapy do not appear warranted, but if performed should include attempts to identify biomarkers predictive of antitumor activity...- The history and mechanism of action of fulvestrantRobert W Carlson
Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
Clin Breast Cancer 6:S5-8. 2005..Methods of exploiting the interactions between these nonsteroidal hormone-dependent mechanisms of resistance and hormonal agents such as fulvestrant are an active area for drug development and clinical investigation... - Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendationsRobert W Carlson
Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
J Natl Compr Canc Netw 4:971-9. 2006.... 
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal womenRobert W Carlson
Stanford Cancer Center, Stanford University, Stanford, CA 94305, USA
J Clin Oncol 28:3917-21. 2010....- A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology GroupRobert W Carlson
Stanford University, Stanford, California 94305 5826, USA
Cancer Invest 24:677-81. 2006..To assess the activity and toxicity of valspodar (PSC-833) in combination with paclitaxel in women with anthracycline refractory, metastatic breast cancer... - Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancerTiffany H Svahn
Division of Oncology, Stanford University, Stanford, California 94305, USA
J Natl Compr Canc Netw 7:115-21. 2009..Adjuvant aromatase inhibitor use increased after the first report of ATAC, with this increase associated with older age, vascular disease, overexpression of HER2, or more advanced stage. Substantial variation was seen among institutions... - NCCN Task Force Report: Adjuvant Therapy for Breast CancerRobert W Carlson
Stanford Hospital and Clinics, Stanford University, Stanford, CA, USA
J Natl Compr Canc Netw 4:S1-26. 2006..This supplement summarizes the background data and ensuing discussion from the Adjuvant Task Force meeting... - Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?Cathie T Chung
Division of Oncology, Stanford University, CA 94305, USA
Clin Breast Cancer 5:S18-23. 2004..There is now substantial medical evidence supporting the use of AIs in postmenopausal women with early-stage, HR-positive breast cancer... - Predictors of local recurrence after breast-conservation therapyKathleen C Horst
Department of Radiation Oncology, Stanford University, CA 94305, USA
Clin Breast Cancer 5:425-38. 2005..The ability to predict for an increased risk of ipsilateral breast tumor recurrence enhances the ability to select optimal local treatment strategies for women considering BCT... - Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozoleRobert W Carlson
Department of Medicine, Stanford University, Palo Alto, CA 94304, USA
Breast Cancer Res Treat 80:S19-26; discussion S27-8. 2003.... - High-dose chemotherapy and stem cell transplantation does not improve relapse-free or overall survival in women with high-risk breast cancerRobert W Carlson
Stanford University, Stanford, CA, USA
Cancer Treat Rev 30:131-7. 2004 - Rational surveillance programs for early stage breast cancer patients after primary treatmentJoseph A Mollick
Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA 94305, USA
Breast Dis 21:47-54. 2004.... - Selecting high priority quality measures for breast cancer quality improvementMichael J Hassett
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Med Care 46:762-70. 2008..We sought to develop a simple, explicit strategy for prioritizing breast cancer quality measures based on their potential to highlight areas where quality improvement efforts could most impact a population... - The role of aromatase inhibitors in early breast cancerCathie T Chung
Division of Oncology, Stanford University, 300 Pasteur Drive, H0274, Stanford, CA 94305, USA
Curr Treat Options Oncol 4:133-40. 2003..New AIs may challenge the position of tamoxifen as the gold standard for the treatment of early stage breast cancer in postmenopausal women... - Update: NCCN breast cancer Clinical Practice GuidelinesRobert W Carlson
Division of Medical Oncology, Stanford Hospital and Clinics, Stanford Cancer Center, 875 Blake Wilbur Drive, Room #2236, Stanford, CA 94305-5826, USA
J Natl Compr Canc Netw 3:S7-11. 2005 - Impaired interferon signaling is a common immune defect in human cancerRebecca J Critchley-Thorne
Division of Hematology, Department of Medicine, Stanford University, Stanford, CA 94305, USA
Proc Natl Acad Sci U S A 106:9010-5. 2009.... - Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell linesAshley A Powell
Department of Surgery, Stanford University School of Medicine, Stanford, California, USA
PLoS ONE 7:e33788. 2012..Here we demonstrate feasibility of performing high dimensional single CTC profiling, providing early insight into CTC heterogeneity and allowing comparisons to breast cancer cell lines widely used for drug discovery... - Trastuzumab-related cardiotoxicity: calling into question the concept of reversibilityMelinda L Telli
Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA, USA
J Clin Oncol 25:3525-33. 2007..To assess the spectrum and reversibility of the cardiotoxicity observed in the adjuvant trastuzumab trials... - Predictors of reexcision findings and recurrence after breast conservationMelanie C Smitt
Department of Radiation Oncology, Stanford University, Stanford, CA, USA
Int J Radiat Oncol Biol Phys 57:979-85. 2003..To identify predictors of reexcision findings and local recurrence in the setting of breast-conserving therapy with radiation... - First-line chemotherapy for metastatic breast cancerMelinda L Telli
Department of Medicine, Division of Medical Oncology, Stanford University, CA, USA
Clin Breast Cancer 9:S66-72. 2009.... - Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancerAnne-Renee Hartman
Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305-5151, USA
Breast Cancer Res Treat 82:61-9. 2003..This all-oral regimen is well tolerated and demonstrates encouraging efficacy in a cohort of heavily pretreated patient with metastatic breast cancer... - Clathrate hydrates of oxidants in the ice shell of EuropaKevin P Hand
Department of Geological and Environmental Sciences, Stanford University, Stanford, California 94305, USA
Astrobiology 6:463-82. 2006..Clathrate-sealed, gas-filled bubbles in the near surface ice could also provide an effective trapping mechanism, though they cannot explain the 5771 A (O2)2 absorption... - Energy, chemical disequilibrium, and geological constraints on EuropaKevin P Hand
Department of Geological and Environmental Sciences, Stanford University, Stanford, California, USA
Astrobiology 7:1006-22. 2007..Such an ocean would be energetically hospitable for terrestrial marine macrofauna. The availability of reductants could be the limiting factor for biologically useful chemical energy on Europa... - Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancerHolbrook E Kohrt
Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA
J Clin Invest 122:1066-75. 2012.... - New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patientsHolbrook E Kohrt
Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA
BMC Cancer 8:66. 2008..Our goal was to develop new models to quantify the risk of NSLN metastasis in SLN-positive patients and to compare predictive capabilities to another widely used model... - Goals and objectives in the management of metastatic breast cancerCathie T Chung
Division of Oncology, Stanford University, Stanford, California, USA
Oncologist 8:514-20. 2003..Both physician and patient perspectives are important in establishing the objectives of treatment, and this process is optimally an interactive and ongoing process throughout the course of disease... - NCCN breast cancer clinical practice guidelines in oncology: an updateRobert W Carlson
Division of Medical Oncology, Stanford Hospital and Clinics, Stanford, California, USA
J Natl Compr Canc Netw 1:S61-3. 2003..The new guidelines for axillary lymph node staging are reported on in a companion article in this issue... - Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?Geoffrey J Yoon
Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA
J Am Coll Cardiol 56:1644-50. 2010.... - mTOR inhibitors in the treatment of breast cancerShaveta Vinayak
Department of Medicine, Stanford University School of Medicine, Stanford, California 94035 5826, USA
Oncology (Williston Park) 27:38-44, 46, 48 passim. 2013..This review will summarize results of preclinical and clinical studies aswell as ongoing clinical trials with mTOR or dual PI3K/mTOR inhibitors... - The decline in breast cancer incidence: real or imaginary?Allison W Kurian
Stanford University School of Medicine, Stanford, CA 94305, USA
Curr Oncol Rep 11:21-8. 2009..However, significant controversy remains as to the timing, causes, generalizability, and longevity of this reported decline in incidence... - Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trialDavid Spiegel
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5718, USA
Cancer 110:1130-8. 2007..Subsequent findings concerning the question of whether such psychosocial support affects survival have been mixed... - Phyllodes tumors of the breast: natural history, diagnosis, and treatmentMelinda L Telli
Department of Medicine, Stanford University, Stanford, CA, USA
J Natl Compr Canc Netw 5:324-30. 2007..Adjuvant systemic therapy is of no proven value. Patients with locally recurrent disease should undergo wide excision of the recurrence with or without subsequent radiotherapy... - Sequencing of endocrine therapies in breast cancer--integration of recent dataRobert W Carlson
Department of Medicine, Stanford University, Palo Alto, CA 94304, USA
Breast Cancer Res Treat 75:S27-32; discussion S33-5. 2002..The establishment of the optimal sequence of the endocrine therapies should offer significant benefits to women with hormone-sensitive metastatic breast cancer... - Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes?John K Chan
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University Medical Center, Stanford Cancer Center 875 Blake Wilbur Drive, MC 5827, Stanford, CA 94305, USA
Gynecol Oncol 102:508-12. 2006..To analyze corpus cancer patients with a breast cancer history for risk of developing aggressive uterine histologic types... - Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancerJamie H Von Roenn
Hematology Oncology, Emory University School of Medicine, Translational Breast Cancer Research Program, Winship Cancer Institute, Atlanta, GA, USA
Clin Breast Cancer 6:163-8. 2005..Based on other trials, longer durations of therapy and/or sequencing of AC and docetaxel may result in a higher pCR rate... - A roundtable discussion of aromatase inhibitors as therapy for breast cancerD Craig Allred
Baylor College of Medicine, Houston, Texas, USA
Breast J 9:213-22. 2003..Finally, recent results suggest that anastrozole may be superior to tamoxifen as adjuvant therapy for early stage disease in postmenopausal women with hormone-responsive disease... - Breast cancerRobert W Carlson
Stanford Hospital and Clinics, USA
J Natl Compr Canc Netw 3:238-89. 2005 - Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelinesBenjamin O Anderson
Department of Surgery, University of Washington, Seattle, 98195, USA
Breast J 12:S3-15. 2006..Future research is needed to better determine how these guidelines can best be implemented in limited-resource settings... - Overview of breast health care guidelines for countries with limited resourcesBenjamin O Anderson
Department of Surgery, University of Washington, Seattle, Washington 98195, USA
Breast J 9:S42-50. 2003..The panels' findings outline specific steps for prioritizing the use of limited resources to decrease the impact of breast cancer around the globe... - NCCN Task Force Report: breast cancer in the older womanRobert W Carlson
J Natl Compr Canc Netw 6:S1-S25; quiz S26-S27. 2008.... - HER2 testing in breast cancer: NCCN Task Force report and recommendationsRobert W Carlson
Stanford Hospital and Clinics
J Natl Compr Canc Netw 4:S1-22; quiz S23-4. 2006..8 to 2.2 or average number of HER2 gene copies/cell in the range of greater than 4 to less than 6 are considered to be borderline, and strategies to assign the HER2 status of such samples are proposed... - Breast cancer in limited-resource countries: treatment and allocation of resourcesAlexandru Eniu
Department of Breast Tumors, Oncology, Cancer Institute I Chiricuta, Cluj Napoca, Romania
Breast J 12:S38-53. 2006..Use of the scheme outlined here should help ministers of health, policymakers, administrators, and institutions in limited-resource settings plan, establish, and gradually expand breast cancer treatment services for their populations... - Guidelines for improving breast health care in limited resource countries: the Breast Health Global InitiativeBenjamin O Anderson
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance, Seattle, WA 98195, USA
J Natl Compr Canc Netw 5:349-56. 2007.... - Invasive breast cancerRobert W Carlson
National Comprehensive Cancer Network
J Natl Compr Canc Netw 5:246-312. 2007 - Reliability of plasma carotenoid biomarkers and its relation to study powerWael K Al-Delaimy
Cancer Prevention and Control Program, Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA 92093 0901, USA
Epidemiology 19:338-44. 2008..We assessed reliability of plasma carotenoid levels over time and how it could influence study power through sample size and effect-size... - Breast cancer risk reductionTherese B Bevers
National Comprehensive Cancer Network
J Natl Compr Canc Netw 5:676-701. 2007 - Cytotoxic T lymphocyte count and survival time in women with metastatic breast cancerJane S Blake-Mortimer
Department of Psychology, University of Adelaide, North Terrace, Adelaide, Australia
Breast J 10:195-9. 2004..Moreover, a reduced CTL count may be a mediator or marker of more rapid disease progression in metastatic breast cancer... - Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancerCheryl L Rock
Cancer Prevention and Control Program, Moores UCSD Cancer Center, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093 0901, USA
Cancer Epidemiol Biomarkers Prev 17:614-20. 2008.... - Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trialJohn P Pierce
Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA 92093 0901, USA
JAMA 298:289-98. 2007..Evidence is lacking that a dietary pattern high in vegetables, fruit, and fiber and low in total fat can influence breast cancer recurrence or survival... - NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancerDonald A Podoloff
J Natl Compr Canc Netw 5:S1-S22; quiz S23-2. 2007..This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology...